Medical Devices - Neuromodulation & Spinal Cord Stimulation
Strategic Profile
The Senza SCS system generates electrical impulses to relieve pain, is implanted by physicians and controlled by patients. The acquisition expanded Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity in neuromodulation and spinal cord stimulation therapies.
Cyborg Score Rationale
Nevro is no longer an independent operating company following its acquisition by Globus Medical in April 2025. Standalone valuation metrics are not applicable.
Top Insights
Acquired by Globus Medical (April 2025) as a $2.5B market opportunity in neuromodulation
HFX platform with proprietary 10 kHz high-frequency spinal cord stimulation technology differentiated in chronic pain treatment
Primarily US-focused revenue base with growing international presence pre-acquisition
Now integrated into Globus Medical's musculoskeletal technology portfolio
Named Competitors
Spinal Modulation — Spinal cord stimulation and neuromodulation therapies
Neuromodulation — Spinal cord stimulation and chronic pain solutions
Spine Solutions — Musculoskeletal and surgical spine technologies
Recent Developments
(April 2025) Acquisition completed by Globus Medical for $250 million